Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | CFO | May 07, 2026 | May 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date May 07, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,146 |
Ending reported balance
After 2026-05-07 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-05-07 · Exercise / conversion · Acquired 2,500 · Balance 63,234 Row 2 · 2026-05-07 · Sale · Disposed 478 · Balance 62,756 Row 3 · 2026-05-07 · Exercise / conversion · Acquired 2,963 · Balance 65,719 Row 4 · 2026-05-07 · Sale · Disposed 573 · Balance 65,146 |
| Employee Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2032-03-16 | Direct | 0 |
Reported balance
After 2026-05-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-07 · Exercise / conversion · Disposed 2,500 · Balance 0 F1: All shares of Axogen, Inc. common stock underlying the employee stock option were fully vested on March 16, 2026. |
| Employee Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2033-03-16 | Direct | 0 |
Reported balance
After 2026-05-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-07 · Exercise / conversion · Disposed 2,963 · Balance 0 F2: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares of Axogen, Inc. common stock underlying the employee stock option were fully vested on March 16, 2026.
F2: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2026 Filed May 8, 2026 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 2,963 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · derivative · entry 6 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,963 shares Expires 2033-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 2,500 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · derivative · entry 5 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2032-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option were fully vested on March 16, 2026. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 573 | $43.67 | $25,022.91 |
DisclosureSEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · nonDerivative · entry 4 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,146 Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 2,963 | $8.27 | $24,504.01 |
DisclosureSEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · nonDerivative · entry 3 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 478 | $43.67 | $20,874.26 |
DisclosureSEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · nonDerivative · entry 2 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,756 Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 2,500 | $8.20 | $20,500.00 |
DisclosureSEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · nonDerivative · entry 1 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · derivative · entry 6 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · derivative · entry 5 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,968 | $32.84 | $64,629.12 |
DisclosureSEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · nonDerivative · entry 4 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,734 F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · nonDerivative · entry 3 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,574 | $32.84 | $51,690.16 |
DisclosureSEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · nonDerivative · entry 2 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,702 F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:10 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000047 · wk-form4_1773864598.xml · nonDerivative · entry 1 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:21 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000038 · wk-form4_1772227303.xml · derivative · entry 3 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:21 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 6,630 | $31.90 | $211,497.00 |
DisclosureSEC source: 0000805928-26-000038 · wk-form4_1772227303.xml · nonDerivative · entry 2 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,276 F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent an open market sale. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:21 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 17,453 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000038 · wk-form4_1772227303.xml · nonDerivative · entry 1 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,906 F1 · shares: This reflects the number of shares that became vested as of February 26, 2026, upon the attainment and certification of certain performance criteria. Read SEC document |
| February 22, 2026 Filed Feb 24, 2026 21:26 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 17,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000032 · wk-form4_1771968389.xml · derivative · entry 3 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 22, 2028 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 22, 2026 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 22, 2028 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 22, 2026 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| February 22, 2026 Filed Feb 24, 2026 21:26 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 6,704 | $35.38 | $237,187.52 |
DisclosureSEC source: 0000805928-26-000032 · wk-form4_1771968389.xml · nonDerivative · entry 2 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,453 F2 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Class A Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). Read SEC document |
| February 22, 2026 Filed Feb 24, 2026 21:26 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000032 · wk-form4_1771968389.xml · nonDerivative · entry 1 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,157 F1 · balance_after: Includes 2,281 shares acquired under the Axogen Employee Stock Purchase Plan on December 31, 2025. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:24 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 14,812 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000805928-25-000176 · wk-form4_1766006686.xml · derivative · entry 3 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,812 shares Expires 2033-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:24 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 14,812 | $29.86 | $442,293.73 |
DisclosureSEC source: 0000805928-25-000176 · wk-form4_1766006686.xml · nonDerivative · entry 2 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,376 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.875 to $29.860 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:24 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 14,812 | $8.27 | $122,495.24 |
DisclosureSEC source: 0000805928-25-000176 · wk-form4_1766006686.xml · nonDerivative · entry 1 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 5,000 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0000805928-25-000160 · wk-form4_1765405121.xml · derivative · entry 6 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 5,000 shares Expires 2032-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares have vested or will vest each 6 months thereafter. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 20,000 | $0.00 Strike: $15.22 | $0.00 |
DisclosureSEC source: 0000805928-25-000160 · wk-form4_1765405121.xml · derivative · entry 5 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2031-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option were fully vested on November 1, 2025 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on November 1, 2023 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vested each 6 months thereafter. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:18 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 2,854 | $31.56 | $90,069.39 |
DisclosureSEC source: 0000805928-25-000160 · wk-form4_1765405121.xml · nonDerivative · entry 4 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,376 Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:18 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 11,533 | $31.56 | $363,935.35 |
DisclosureSEC source: 0000805928-25-000160 · wk-form4_1765405121.xml · nonDerivative · entry 3 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,230 Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 5,000 | $8.20 | $41,000.00 |
DisclosureSEC source: 0000805928-25-000160 · wk-form4_1765405121.xml · nonDerivative · entry 2 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 20,000 | $15.22 | $304,400.00 |
DisclosureSEC source: 0000805928-25-000160 · wk-form4_1765405121.xml · nonDerivative · entry 1 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2025 Filed May 16, 2025 22:40 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 26,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000066 · wk-form4_1747435228.xml · derivative · entry 1 Hartley Lindsey Marie · CIK 0002068693 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on May 12, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on May 12, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F2 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on May 12, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on May 12, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.